Page last updated: 2024-08-25

trimegestone and dydrogesterone

trimegestone has been researched along with dydrogesterone in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's5 (83.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kenemans, P; Smolders, RG; Teerlink, T; van Baal, WM; van der Mooren, MJ1
Dräger, AM; Huijgens, PC; Kenemans, P; Stehouwer, CD; Thijs, A; van Baal, WM; van der Mooren, MJ1
Kenemans, P; Post, MS; Rosing, J; Stehouwer, CD; Van Baal, WM; Van Der Mooren, MJ; Zweegman, S1
Kenemans, P; Post, MS; Stehouwer, CD; Teerlink, T; van der Mooren, MJ; Verhoeven, MO1
Bonnar, J; Brosnan, J; Conard, J; Hellgren, M; Kluft, C; Norris, LA1
Conard, J; Hellgren, M; Kluft, C; Norris, L1

Trials

6 trial(s) available for trimegestone and dydrogesterone

ArticleYear
Hormone replacement therapy and plasma homocysteine levels.
    Obstetrics and gynecology, 1999, Volume: 94, Issue:4

    Topics: Dydrogesterone; Estradiol; Fasting; Female; Homocysteine; Hormone Replacement Therapy; Humans; Middle Aged; Progesterone Congeners; Promegestone; Prospective Studies; Time Factors

1999
Effects of hormone replacement therapy on blood platelets.
    European journal of clinical investigation, 2002, Volume: 32, Issue:8

    Topics: Antigens, CD; Arteriosclerosis; Biomarkers; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Female; Flow Cytometry; Humans; Middle Aged; P-Selectin; Platelet Activation; Platelet Membrane Glycoproteins; Progesterone Congeners; Promegestone; Prospective Studies; Tetraspanin 30

2002
Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.
    British journal of haematology, 2002, Volume: 119, Issue:4

    Topics: Activated Protein C Resistance; Analysis of Variance; Double-Blind Method; Drug Combinations; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Factor VIII; Factor XI; Female; Humans; Middle Aged; Postmenopause; Promegestone; Prospective Studies

2002
Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women.
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:9

    Topics: Arginine; Biomarkers; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Female; Humans; Isomerism; Middle Aged; Progesterone Congeners; Promegestone; Risk Factors; Spectrometry, Fluorescence

2003
Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:2

    Topics: Administration, Oral; Adult; Aged; Blood Coagulation Tests; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Factor V; Female; Fibrinolysis; Hemostasis; Humans; Middle Aged; Progestins; Promegestone; Protein C; Protein S; Risk Factors; Venous Thrombosis

2008
Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
    Maturitas, 2009, Mar-20, Volume: 62, Issue:3

    Topics: Adult; Aged; Biomarkers; Blood Coagulation Factors; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Dydrogesterone; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Fibrinolysis; Humans; Lipids; Middle Aged; Postmenopause; Progestins; Promegestone; Risk Factors; Thromboembolism; Uterine Hemorrhage

2009